新型冠状病毒SARS-CoV-2及临床相关药物研究进展  

Advances in Research on SARS-CoV-2 and Relevant Drugs Clinically Used

作　　者：顾云双 李明峰 孙建国[1] GU Yunshuang;LI Mingfeng;SUN Jianguo(Key Laboratory of Drug Metabolism and Pharmacokinetics,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学药物代谢动力学重点实验室,江苏南京210009

出　　处：《药学进展》2020年第3期222-231,共10页Progress in Pharmaceutical Sciences

摘　　要：新型冠状病毒SARS-CoV-2是一种β属的冠状病毒,与SARS-CoV均以血管紧张素转换酶2为侵入宿主细胞的受体。在临床上,病毒感染患者表现出呼吸道和肺部损伤。以SARS-CoV作为参照研究SARS-CoV-2是目前的常用方法。主要介绍了冠状病毒的分类、结构和生命周期、血管紧张素转换酶2在SARS-CoV中的作用,并且总结了SARS-CoV-2的相关研究进展和临床治疗药物的药代动力学特性,为医药工作者充分了解SARS-CoV-2的发展过程以及相关药物研发提供参考。As aβ-type coronavirus,SARS-CoV-2 uses angiotensin converting enzyme 2(ACE2)as the receptor to invade the host cell like SARS-CoV.Clinically,patients mainly showed respiratory infection and lung injury.Currently,SARS-CoV is commonly used as a comparison to study SARS-CoV-2.This paper introduces the classification,structure and life cycle of coronavirus and the role of ACE2 in SARS-CoV,and summarizes the relevant research progress and pharmacokinetic profiles of possible therapeutic drugs of SARSCoV-2,so as to provide reference for better understanding of the SARS-CoV-2 evolution process and R&D of the related drugs.

关 键 词：新型冠状病毒 SARS-CoV-2 NCP COVID-19 药物代谢动力学 

分 类 号：R978[医药卫生—药品]